Kapil Arya
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
Also affiliated: Lovely Professional University (2020–2022); Arkansas Children's Hospital (2018–2024); State University of New York (2016); SUNY Downstate Health Sciences University (2016–2017); University of Arkansas Medical Center (2024); Govind Ballabh Pant Hospital (2012)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Kapil Arya's research focuses on spinal muscular atrophy (SMA), investigating treatment outcomes and best practices for patients with Type 1 and Type 2 SMA. His work includes an expanded access program for risdiplam and a multicenter retrospective cohort study on the outcomes of early-treated infants with SMA. Arya also contributes to the understanding of neurological conditions, having published on seizures in patients with myelomeningocele and on specific seizure types such as simple partial seizures and epilepsia partialis continua. Additionally, his research extends to drug delivery systems, with a publication on advanced systems for treating Huntington's disease. He has co-authored publications with several collaborators at the University of Arkansas for Medical Sciences, including Aravindhan Veerapandiyan, Abhilash Thatikala, and Praveen Kumar Ramani. Arya's scholarship metrics include an h-index of 11, with 39 total publications and 606 total citations.
Metrics
- h-index: 11
- Publications: 39
- Citations: 617
Selected Publications
-
GAD65 Antibody–Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature (2026)
-
Expanding the Genotypic Spectrum of <i>SLC18A2</i> Mutation–Related Disorder—A Novel Mutation and Review of Literature (2026)
-
CACNA1A Channelopathies and Associated Eye Movement Disorders (2026)
-
Essential Components of Child Neurology Training: Program Director Consensus Recommendations (2025)
-
Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study (2024)
-
Considerations for Treatment in Clinical Care of Spinal Muscular Atrophy Patients (2024)
-
Arthur L. Rose, M.D.(1932-2022): A Requiem (2023)
-
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy (2022)
-
Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study (2021)
-
Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series (2020)
-
Combination molecular therapies for type 1 spinal muscular atrophy (2020)
-
BAG3 Myopathy Presenting With Prominent Neuropathic Phenotype and No Cardiac or Respiratory Involvement: A Case Report and Literature Review (2020)
-
Spinal muscular atrophy care in the COVID‐19 pandemic era (2020)
-
Electroclinical findings of SYNJ1 epileptic encephalopathy (2020)
-
Reflex Photosensitive Epilepsy (2019)
Collaboration Network
Top Collaborators
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study
- Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study
- Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study
- Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study
- Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
Similar Researchers
Based on overlapping research topics